In Brief: Oxymedyca
This article was originally published in The Gray Sheet
Executive Summary
Oxymedyca: Company's biomedical division begins limited marketing of its HIV-RIT in vitro rapid enzyme immunoassay screening assay for antibodies to HIV-1 and HIV-2 in serum, plasma or whole blood. The qualitative, initial screening assay, which has both sensitivity and specificity of 99.9%, takes 15 minutes to complete...